Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dupilumab reduces exacerbations and improves lung function in patients with chronic obstructive pulmonary disease and emphysema: Phase 3 randomized trial (BOREAS).
Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Bafadhel M, Christenson SA, Papi A, Singh D, Laws E, Dakin P, Maloney J, Lu X, Bauer D, Bansal A, Robinson LB, Abdulai RM. Bhatt SP, et al. Among authors: robinson lb. Respir Med. 2024 Oct 30;236:107846. doi: 10.1016/j.rmed.2024.107846. Online ahead of print. Respir Med. 2024. PMID: 39481660 Free article.
Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation.
Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Bafadhel M, Christenson SA, Papi A, Singh D, Laws E, Patel N, Yancopoulos GD, Akinlade B, Maloney J, Lu X, Bauer D, Bansal A, Abdulai RM, Robinson LB; NOTUS Study Investigators. Bhatt SP, et al. Among authors: robinson lb. N Engl J Med. 2024 Jun 27;390(24):2274-2283. doi: 10.1056/NEJMoa2401304. Epub 2024 May 20. N Engl J Med. 2024. PMID: 38767614 Clinical Trial.
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts.
Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Cole J, Bafadhel M, Christenson SA, Papi A, Singh D, Laws E, Mannent LP, Patel N, Staudinger HW, Yancopoulos GD, Mortensen ER, Akinlade B, Maloney J, Lu X, Bauer D, Bansal A, Robinson LB, Abdulai RM; BOREAS Investigators. Bhatt SP, et al. Among authors: robinson lb. N Engl J Med. 2023 Jul 20;389(3):205-214. doi: 10.1056/NEJMoa2303951. Epub 2023 May 21. N Engl J Med. 2023. PMID: 37272521 Clinical Trial.
Assessment of long-term safety and efficacy of dupilumab in children with asthma (LIBERTY ASTHMA EXCURSION): an open-label extension study.
Bacharier LB, Maspero JF, Katelaris CH, Fiocchi AG, Gagnon R, de Mir I, Guilbert TW, Jackson DJ, Staudinger HW, Laws E, Mannent LP, Akinlade B, Maloney J, Tawo K, Khokhar FA, Li N, Hardin M, Abdulai RM, Lederer DJ, Robinson LB; Liberty Asthma EXCURSION Investigators. Bacharier LB, et al. Among authors: robinson lb. Lancet Respir Med. 2024 Jan;12(1):45-54. doi: 10.1016/S2213-2600(23)00303-X. Epub 2023 Nov 10. Lancet Respir Med. 2024. PMID: 37956679
Application of Asthma Prediction Tools in a Cohort of Infants with Severe Bronchiolitis.
Fabiano Filho RC, Geller RJ, Candido Santos L, Espinola JA, Robinson LB, Camargo CA Jr. Fabiano Filho RC, et al. Among authors: robinson lb. Pediatr Allergy Immunol Pulmonol. 2023 Sep;36(3):110-114. doi: 10.1089/ped.2023.0016. Epub 2023 Aug 28. Pediatr Allergy Immunol Pulmonol. 2023. PMID: 37638804 Free PMC article.
Maternal Hypertensive Disorders of Pregnancy and the Risk of Childhood Asthma.
Arroyo AC, Robinson LB, James K, Li S, Faridi MK, Hsu S, Dumas O, Liu AY, Druzin M, Powe CE, Camargo CA Jr. Arroyo AC, et al. Among authors: robinson lb. Ann Am Thorac Soc. 2023 Sep;20(9):1367-1370. doi: 10.1513/AnnalsATS.202212-994RL. Ann Am Thorac Soc. 2023. PMID: 37233740 Free PMC article. No abstract available.
Proton Pump Inhibitors in Allergy: Benefits and Risks.
Robinson LB, Ruffner MA. Robinson LB, et al. J Allergy Clin Immunol Pract. 2022 Dec;10(12):3117-3123. doi: 10.1016/j.jaip.2022.09.022. Epub 2022 Sep 23. J Allergy Clin Immunol Pract. 2022. PMID: 36162802 Free PMC article. Review.
63 results